Literature DB >> 19208976

Preventive strategies for frequent outbreaks of Japanese encephalitis in Northern India.

Vandana Saxena1, Tapan N Dhole.   

Abstract

Japanese encephalitis (JE) remains the most important cause of acute viral encephalitis and continues to spread to hitherto unaffected regions like Indonesia, Pakistan and Australia. Approximately 60% of the world population inhabits JE endemic areas. Despite its restricted range mostly in the developing countries,a high annual incidence of 50,000 cases and about 10,000 deaths has been reported. Disease can be fatal in 25% ases. Magnitude of the problem is even more alarming since the survivors are left with serious long-term neuropsychiatric sequelae. Almost every two years,epidemics of JE occur in Indian subcontinent with a high mortality. JE virus infection results in different disease manifestations in host from mild subclinical febrile illness to clinical infections leading to encephalitis. No antiviral treatment is so far available for JE. The prevention of JE can be achieved by controlling the vector or by immunization regime. The vector control in the rural areas,which are the worst affected ones,is practically almost impossible. Three vaccines that have been implicated against JE include inactivated mouse brain derived, inactivated cell culture derived and cell culture derived live attenuated JE vaccine. But each has its own limitation. Currently,attempts to synthesize recombinant DNA vaccine are being made. New therapeutics are on the way of development like use of minocycline, short interfering RNA, arctigenin, rosmarinic acid, DNAzymes etc. However,the immune mechanisms that lead to JE are complex and need to be elucidated further for the development of therapeutics as well as safe and efficacious JE vaccines.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19208976     DOI: 10.1007/s12038-008-0069-9

Source DB:  PubMed          Journal:  J Biosci        ISSN: 0250-5991            Impact factor:   1.826


  79 in total

1.  Study of the outbreak of Japanese encephalitis in Lakhimpur district of Assam in 1989.

Authors:  A Vajpayee; P N Dey; A K Chakraborty; M S Chakraborty
Journal:  J Indian Med Assoc       Date:  1992-05

2.  Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.

Authors:  Thomas P Monath; Farshad Guirakhoo; Richard Nichols; Sutee Yoksan; Robert Schrader; Chris Murphy; Paul Blum; Stephen Woodward; Karen McCarthy; Danell Mathis; Casey Johnson; Philip Bedford
Journal:  J Infect Dis       Date:  2003-10-03       Impact factor: 5.226

3.  Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodies.

Authors:  J Kimura-Kuroda; K Yasui
Journal:  J Immunol       Date:  1988-11-15       Impact factor: 5.422

4.  Clinical features & prognostic indicators of Japanese encephalitis in children in Lucknow (India).

Authors:  R Kumar; A Mathur; A Kumar; S Sharma; S Chakraborty; U C Chaturvedi
Journal:  Indian J Med Res       Date:  1990-09       Impact factor: 2.375

5.  A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice.

Authors:  G J Chang; A R Hunt; B Davis
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

6.  DNAzyme-mediated inhibition of Japanese encephalitis virus replication in mouse brain.

Authors:  Mohan Babu Appaiahgari; Sudhanshu Vrati
Journal:  Mol Ther       Date:  2007-06-19       Impact factor: 11.454

7.  A 27 amino acid coding region of JE virus E protein expressed in E. coli as fusion protein with glutathione-S-transferase elicit neutralizing antibody in mice.

Authors:  S A Seif; K Morita; A Igarashi
Journal:  Virus Res       Date:  1996-07       Impact factor: 3.303

8.  Avipox virus-vectored Japanese encephalitis virus vaccines: use as vaccine candidates in combination with purified subunit immunogens.

Authors:  E Konishi; S Pincus; E Paoletti; R E Shope; P W Wason
Journal:  Vaccine       Date:  1994-05       Impact factor: 3.641

9.  Cell-mediated immune responses in healthy children with a history of subclinical infection with Japanese encephalitis virus: analysis of CD4+ and CD8+ T cell target specificities by intracellular delivery of viral proteins using the human immunodeficiency virus Tat protein transduction domain.

Authors:  Priti Kumar; Venkatramana D Krishna; Paramadevanapalli Sulochana; Gejjehalli Nirmala; Maganti Haridattatreya; Vijaya Satchidanandam
Journal:  J Gen Virol       Date:  2004-02       Impact factor: 3.891

10.  Epidemiological profile of Japanese encephalitis in Gorakhpur district, Uttar Pradesh, 1982-1988.

Authors:  N J Kar; D Bora; R C Sharma; J Bhattacharjee; K K Datta; R S Sharma
Journal:  J Commun Dis       Date:  1992-09
View more
  16 in total

1.  Mass scale screening of common arboviral infections by an affordable, cost effective RT-PCR method.

Authors:  Debjani Taraphdar; Arindam Sarkar; Shyamalendu Chatterjee
Journal:  Asian Pac J Trop Biomed       Date:  2012-02

2.  Larvicidal, repellent, and ovicidal activity of marine actinobacteria extracts against Culex tritaeniorhynchus and Culex gelidus.

Authors:  L Karthik; K Gaurav; K V Bhaskara Rao; G Rajakumar; A Abdul Rahuman
Journal:  Parasitol Res       Date:  2010-12-10       Impact factor: 2.289

3.  Inhibition of HIV-1 Integrase gene expression by 10-23 DNAzyme.

Authors:  Nirpendra Singh; Atul Ranjan; Souvik Sur; Ramesh Chandra; Vibha Tandon
Journal:  J Biosci       Date:  2012-07       Impact factor: 1.826

4.  Decreases in Both the Seroprevalence of Serum Antibodies and Seroprotection against Japanese Encephalitis Virus among Vaccinated Children.

Authors:  Ran Wang; Lyu Xie; Na Gao; Dongying Fan; Hui Chen; Peigang Wang; Hongning Zhou; Jing An
Journal:  Virol Sin       Date:  2019-03-25       Impact factor: 4.327

5.  DDT & deltamethrin resistance status of known Japanese encephalitis vectors in Assam, India.

Authors:  Sunil Dhiman; Bipul Rabha; P K Talukdar; N G Das; Kavita Yadav; Indra Baruah; Lokendra Singh; Vijay Veer
Journal:  Indian J Med Res       Date:  2013-12       Impact factor: 2.375

6.  Development of a vaccine to prevent Japanese encephalitis: a brief review.

Authors:  Viroj Wiwanitkit
Journal:  Int J Gen Med       Date:  2009-12-29

7.  Pediatricians' perceptions of vaccine effectiveness and safety are significant predictors of vaccine administration in India.

Authors:  Lisa M Gargano; Naveen Thacker; Panna Choudhury; Paul S Weiss; Rebecca M Russ; Karen Pazol; Manisha Arora; Walter A Orenstein; Saad B Omer; James M Hughes
Journal:  Int Health       Date:  2013-07-29       Impact factor: 2.473

8.  Clinical presentation, etiology, and survival in adult acute encephalitis syndrome in rural Central India.

Authors:  Rajnish Joshi; Pradyumna Kumar Mishra; Deepti Joshi; S R Santhosh; M M Parida; Prabha Desikan; Nitin Gangane; S P Kalantri; Arthur Reingold; John M Colford
Journal:  Clin Neurol Neurosurg       Date:  2013-05-01       Impact factor: 1.876

9.  Epidemiological concordance of Japanese encephalitis virus infection among mosquito vectors, amplifying hosts and humans in India.

Authors:  J Borah; P Dutta; S A Khan; J Mahanta
Journal:  Epidemiol Infect       Date:  2012-02-24       Impact factor: 4.434

10.  Antiviral and neuroprotective role of octaguanidinium dendrimer-conjugated morpholino oligomers in Japanese encephalitis.

Authors:  Arshed Nazmi; Kallol Dutta; Anirban Basu
Journal:  PLoS Negl Trop Dis       Date:  2010-11-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.